Results 131 to 140 of about 1,993,579 (343)

Indolealkylamines: Biotransformations and Potential Drug–Drug Interactions [PDF]

, 2008
Ai‐Ming Yu
openalex   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

Biologically Based Complementary and Alternative Medicine Use in Breast Cancer Patients and Possible Drug-Drug Interactions

, 2023
Anna Marie Debes, Alexander Köenig, Dorothea Strobach, Timo Schinkoethe, Marie Forster, Nadia Harbeck, Rachel Wuerstlein   +6 more
openalex   +2 more sources

PHARMACOKINECTS STUDY TO EVALUATE DRUG-DRUG INTERACTIONS (DDI) BETWEEN HZN-825 AND PIRFENIDONE/NINTEDANIB [PDF]

, 2023
Yang Song, Krischan J Hudson, ZHAN YE, Wei Chen, Lisa Hawley, Jennifer Zarzoso, John Rogowski, Nicholas Siebers, GENE VOSKUHL, YAJING SUN, Y. Xin   +10 more
openalex   +1 more source

A novel Malonamide Periodic Mesoporous Organosilica (PMO) for controlled Ibuprofen release [PDF]

, 2015
Controlled drug release gained a sharply increasing interest over recent years. Multiple materials have been screened as possible drug carriers, ranging from biodegradable polymers to hydroxyapatite[1].
Clerick, Sander, De Canck, Els, De Clercq, Jeriffa, Libbrecht, Wannes, van den Berg, Otto, Van Der Voort, Pascal   +5 more
core  

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

Molecular Oncology, EarlyView.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang, Qian Sun, Daniel Novak, Lei Zhu, Juliane Poelchen, Tamara Steinfass, Yiman Wang, Viktor Umansky, Jochen Utikal   +8 more
wiley   +1 more source

Nurses' Awareness and Perception of Drug-Drug and Drug Food Interactions

Evidence-Based Nursing Research
Context: The issue of drug interactions is a global concern. Studies reported a high prevalence of drug interactions worldwide. The drug-drug interaction (DDIs) and drug-food interactions (DFIs) are often predictable and preventable.
Hend A. E. Elshenawi, Yasmin F. M. Abed Elazeem   +1 more
doaj   +1 more source

Isolated conjugated hyperbilirubinemia with rifampicin and cross-reaction with rifabutin: A drug-endogenous substance interaction case report

, 2023
S. Cohen, Charlotte Devant, Laure Delaval, Caroline Charlier, Étienne Canouï, Laurent Chouchana   +5 more
openalex   +1 more source